Table 2
Clinical results after indomethacin treatment
| Protocol group (n=46) | ECHO group (n=47) | p Value | |
|---|---|---|---|
| Age at treatment (days) | 2.6 (1.9) | 2.3 (1.1) | 0.999 |
| Doses of indomethacin (number) | 3.2 (1.4) | 1.6 (0.9) | <0.01 |
| Closure rates | 41 (89.1%) | 41 (87.2%) | 0.999 |
| Reopening rates | 4 (8.7%) | 5 (10.6%) | 0.999 |
| Ligation rates | 5 (10.9%) | 5 (10.6%) | 0.999 |
| Complications | |||
| Hypoglycaemia | 21 (45.7%) | 10 (21.3%) | 0.02 |
| Necrotising enterocolitis | 4 (8.7%) | 4 (8.5%) | 0.999 |
| Impaired urine output | 26 (56.5%) | 12 (25.5%) | 0.0046 |
| Gastrointestinal bleeding | 18 (39.1%) | 8 (17.0%) | 0.03 |
| IVH (all grades) | 9 (19.6%) | 9 (19.1%) | 0.999 |
| IVH (grades 3 and 4) | 3 (6.5%) | 3 (6.4%) | 0.999 |
| Neonatal mortality | 9 (19.6%) | 9 (19.2%) | 0.999 |
| Chronic lung disease in survivors | 9 (24.3%) | 10 (26.3%) | 0.999 |
-
The values are mean (SD) or number of infants (percentage).
